Serafini Paolo, Mgebroff Stephanie, Noonan Kimberly, Borrello Ivan
Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami, School of Medicine, Miami, Florida 33136, USA.
Cancer Res. 2008 Jul 1;68(13):5439-49. doi: 10.1158/0008-5472.CAN-07-6621.
Tumor-induced T-cell tolerance is a major mechanism that facilitates tumor progression and limits the efficacy of immune therapeutic interventions. Regulatory T cells (Treg) play a central role in the induction of tolerance to tumor antigens, yet the precise mechanisms regulating its induction in vivo remain to be elucidated. Using the A20 B-cell lymphoma model, here we identify myeloid-derived suppressor cells (MDSC) as the tolerogenic antigen presenting cells capable of antigen uptake and presentation to tumor-specific Tregs. MDSC-mediated Treg induction requires arginase but is transforming growth factor-beta independent. In vitro and in vivo inhibition of MDSC function, respectively, with NOHA or sildenafil abrogates Treg proliferation and tumor-induced tolerance in antigen-specific T cells. These findings establish a role for MDSCs in antigen-specific tolerance induction through preferential antigen uptake mediating the recruitment and expansion of Tregs. Furthermore, therapeutic interventions, such as in vivo phosphodiesterase 5-inhibition, which effectively abrogate the immunosuppressive role of MDSCs and reduce Treg numbers, may play a critical role in delaying and/or reversing tolerance induction.
肿瘤诱导的T细胞耐受是促进肿瘤进展并限制免疫治疗干预效果的主要机制。调节性T细胞(Treg)在诱导对肿瘤抗原的耐受中起核心作用,但其在体内诱导的精确机制仍有待阐明。利用A20 B细胞淋巴瘤模型,我们在此确定髓源性抑制细胞(MDSC)是能够摄取抗原并将其呈递给肿瘤特异性Treg的致耐受性抗原呈递细胞。MDSC介导的Treg诱导需要精氨酸酶,但不依赖于转化生长因子-β。分别用诺哈西肽或西地那非在体外和体内抑制MDSC功能,可消除Treg增殖以及肿瘤诱导的抗原特异性T细胞耐受。这些发现确立了MDSC在通过优先摄取抗原介导Treg的募集和扩增从而诱导抗原特异性耐受中的作用。此外,诸如体内磷酸二酯酶5抑制等治疗干预措施可有效消除MDSC的免疫抑制作用并减少Treg数量,可能在延迟和/或逆转耐受诱导中起关键作用。